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1. Introduction 
Schizophrenia is a devastating psychiatric disorder that impairs mental and social 
functions. Although loose descriptions resembling schizophrenia are obtained in texts 
dating back more than two thousand years, the first comprehensive and scientific 
definition was described by the late 1800s as dementia precox by Emil Kraepelin. In 
1911 Eugene Bleuler firstly applied the schizophrenia name, as a mental illness with 
chronic psychotic symptoms, but not a dementia [1]. After a lot of emerging approaches 
it became necessary to develop more stringent diagnostic criteria which can be 
described by two major classification systems, Diagnostic Statistical Manual (DSM I-V) 
and International Classification of Disease. 
1.1 Symptoms of schizophrenia 
The disease manifests itself with positive symptoms (hallucinations, delusions and 
thought disorder), negative symptoms (deficits in social interaction, emotional 
expression, motivation, speech difficulties and abnormalities) and cognitive 
dysfunctions (impaired attention, information processing, problem-solving, verbal and 
visual learning and memory); therefore, schizophrenia is considered as a complex, 
multifactorial disease. The negative and cognitive symptoms are more persistent and 
chronic, while the psychotic symptoms follow a certain episodic pattern. Onset of 
behavioral symptoms appears from adolescence until the age of 40 for most patients, in 
men usually occurs earlier than in women. The development, course and outcome of the 
disease has high inter individual variability. Several other, non-specific sings, can also 
be observed in schizophrenia; such as sensory gating disturbance, motor behavioral 
changes and decreased pain sensitivity. 
Sensory gating, as measured by prepulse inhibition of the acoustic startle reflex (PPI), 
describes neurological processes of filtering out redundant or unnecessary stimuli in the 
brain and it prevents an overload of irrelevant information in the higher cortical centers 
of the brain [2]. Sensory gating, as a non specific sign, is reduced in a variety of 
neuropsychiatric disorders (e.g. Huntingtons’s disease, Tourette’s syndrome, autism, 
bipolar or panic disorder) including schizophrenia [3-5].  
Schizophrenic patients frequently manifest abnormalities in both the extent and nature 
of motor activity [6]. Slowing of motor activity is common in schizophrenia, and it is 
variably associated with negative and depressive symptom clusters. Excessive motor 
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activity, often apparently purposeless, is more often associated with exacerbations of 
positive symptoms.  
Various clinical case studies have described that both prevalence and intensity of pain 
appear to be diminished, for example, appendicitis, fractures and abdominal surgical 
emergencies seems to be reduced in persons with schizophrenia [7]. Thermal, electrical, 
cold and tactile stimulation have been utilized to assess pain threshold and pain 
tolerance in schizophrenia [8-11]. A significant part of these experimental pain studies 
concluded that persons with schizophrenia appear to be less sensitive to pain compared 
to healthy controls. 
1.2 Epidemiology and etiology 
Schizophrenia affects approximately 1% of the population worldwide [12, 13]. Despite 
the fact that more than one hundred thousand schizophrenia-related publications can be 
found in Pubmed, exact etiology and pathomechanism of schizophrenia is not known 
until now. Many studies revealed relationship between the degree of urbanicity and risk 
of schizophrenia, strongly supporting the proposition that some factors associated with 
urbanicity may be causally related to schizophrenia [1]. Such effect may be: urban-rural 
differences in rates of cannabis and other substance use, degree of social stress and 
social connectedness, poverty, environmental toxins or vitamin D deficiency. 
The gender differences in the clinical expression and outcome of schizophrenia have 
long been recognized [1], and meta-analyses also revealed that males have a higher 
lifetime risk of developing schizophrenia with a male-female relative risk of about 1.4 
[1]. 
There are also some other factors which are present in the unfolding of schizophrenia. It 
has long been known that patients, who subsequently received a diagnosis of 
schizophrenia, are often born in winter. One possible explanation might be that the 
second trimester coincides with the flu seasons, which may increase the risk of 
schizophrenia. Several studies have revealed that those children, whose mother suffered 
from infections (flu, toxoplasma, rubella) during pregnancy, are more likely to develop 
schizophrenia [1]. Older paternal age at conception has been linked to an approximate 
doubling of the risk for developing schizophrenia, impaired spermatogenesis leading to 
an increased likelihood of de novo mutation and aberrant epigenetic regulation has been 
advanced as explanations. 
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Genetics play a major role in the etiology of schizophrenia, however, none of the 
identified risk genes are specific to schizophrenia, but rather indicate a general 
vulnerability to mental health disorders [14]. The chance of developing schizophrenia in 
a person is about 9-16% if one parent is affected and 40-68% if both are ill. Siblings and 
dizygotic twins share 50% of their genetic material, and if either of them has 
schizophrenia, then the risk of the other developing the illness is 10–15% [1]. However, 
monozygotic twins share 100% of their genetic material, and if one twin has 
schizophrenia, the risk of schizophrenia in the other is about 40–50%. In the largest 
published familial schizophrenia cohort, Toulopoulou et al. demonstrated that a major 
portion of phenotypic correlation between schizophrenia patients in certain cognitive 
measures could be explained by shared multiple genes [2]. 
Several “structural” chromosomal abnormalities have been described in schizophrenia, 
which might harbor a risk gene or genes for schizophrenia. Genes or gene products 
identified in the pathogenetic background of schizophrenia include neuroregulin 1 
(which play an important role in the development of the nervous system), dysbindin 
(affecting hippocampal based cognitive processes during juvenile brain development), 
disrupted in schizophrenia 1 (DISC1, having a role in both neural signaling and 
development), dopamine receptors D1–D4; catechol-O-methyl-transferase (is critically 
involved in dopamine (DA) metabolism) and metabotropic glutamate receptors [15, 16]. 
1.3 Neuroanatomical changes 
Several abnormalities in the brain structure were detected in schizophrenia [4, 17, 18]. 
Enlarged brain ventricles are seen in some schizophrenics, indicating a deficit in the 
volume of brain tissue. Advances in the in vivo magnetic resonance imaging technology 
have led to the identification of reductions in temporal lobe structures, in particular the 
hippocampus, amygdala, the superior temporal gyrus, furthermore the prefrontal cortex, 
the thalamus, anterior cingulate cortex and corpus callosum [17]. Abnormalities in the 
superior temporal gyrus correlate with positive symptoms, while the gray matter density 
reductions in medial temporal lobes correlate with memory impairments. Reduced white 
matter structures such as corpus callosum and other fiber tracts have also been reported 
in schizophrenia, and these alterations appear to be correlated with cognitive 
impairments [17]. 
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1.4 Pathophysiological changes  
Several neurotransmitter abnormalities such as the dopaminergic, glutamatergic (GLU), 
GABAergic (γ-aminobutyric acid) deficits play important roles in schizophrenia [19, 
20].  
The dopamine hypothesis of schizophrenia originates from the 1960s from the 
observations that psychostimulant drugs (e.g.: amphetamine), which increase neuronal 
dopamine levels, can lead to psychotic symptoms that are almost indistinguishable from 
schizophrenia [20]. It has been shown that the subcortical hyper-dopaminergic state is 
associated with hypo-dopaminergic state of the frontal cortex [21]. This theory suggests 
that normal, baseline mesolimbic dopamine output yields normal psychiatric 
functioning and the positive symptoms of schizophrenia are a direct result of too much 
DA neuronal firing originating in the midbrain and allowing excessive DA release and 
activity in limbic structures. The excess DA might actually be derived from the 
abnormal GLU neurocircuitry system [20, 21].  Descending glutamate pathway, which 
starts in the frontal cortex regulates the mesolimbic DA neurons by excitatory 
ionotropic N-methyl-D-aspartate (NMDA) glutamate receptors. This sequence of 
neurons consists of several stops (Fig.1.). Normally, a fully functioning primary 
glutamate neuron (pyramidal neuron) fires upon a smaller GABA interneuron which 
releases inhibitory GABA onto a secondary GLU pyramidal neuron (which now is the 
third neuron in this cascade) causing it to lower its firing rate. This low GLU tone at this 
second GLU neuron is normal. The fourth neuron is dopaminergic in the midbrain and 
fires at a normal rate. The NMDA receptor hypo-functioning hypothesis is a newer 
hypothesis, formulated roughly two decades ago, suggests that NMDA receptors 
attached to the GABA interneurons situated between the primary and secondary GLU 
cortical neurons are responsible for the symptoms. The loss of GABA activity will 
cause an abnormal graduation of the secondary GLU neuron‘s firing rate. This 
excessive GLU tone has massive impact on the DA mesolimbic pathway causing 
increased DA neuronal activity (the dopamine hypothesis) thereby resulting psychotic 
symptoms [21].  
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Figure 1. Normal GLU-GABA-GLU-DA neurocircuit loop with non-psychotic state (left side). 
Abnormal GLU-GABA-GLU-DA neurocircuit loop generates psychotic positive symptoms of 
schizophrenia (right side). 
 
Different DA pathways play a role in the development of negative and cognitive 
symptoms, which suggests that normal psychiatric functioning occurs as a result of 
baseline or normal dopamine output reaching the frontal cortex, but the negative 
symptoms of schizophrenia are a direct result of too little DA neuronal firing originating 
in the midbrain and allowing poor DA release and activity of the frontal cortex [17, 21] 
(Fig.2.). A similar relationship exists in the first three steps with a primary GLU neuron, 
a GABA interneuron, and a secondary GLU neuron interacting. Next, however, is a 
synapse further down in the midbrain with yet another GABA interneuron which 
impinges upon DA neuronal projections that proceed back to the frontal cortex. The 
dysfunctional NMDA receptors cause lost tone of GABA, so the secondary GLU 
neuron will be again hyperactive and this neuron causes much higher GABA 
concentrations, which inhibits dopamine neurons. This type of circuit can become 
defective due to abnormal GLU NMDA receptors located on GABA interneurons, or 
any other impingement on the circuit that would result in final downstream of DA 
common pathway.  
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Figure 2. Normal GLU-GABA-GLU-GABA-DA neuronal circuitry (left side). Abnormally GLU-
GABA-GLU-GABA-DA neuronal circuitry may cause negative symptoms (right side).  
1.5 Animal models 
In order to understand the biological mechanisms underlying a complex disorder and in 
search of novel drug targets, valid animal models are necessary. 
Nowadays, there are many animal models of schizophrenia, which to a smaller or 
greater extent (showing one or several symptoms) reflect the key symptoms observed in 
human patients suffering from this disease. Rodent models of schizophrenia mostly 
display symptoms analogous to the negative and cognitive signs. Social withdrawal and 
disturbed sensory motor gating are identified as the equivalent of negative symptoms 
[22-26]. Positive symptoms (e.g. hallucinations, delusions) observed in patients 
diagnosed with schizophrenia are of particular importance; however because of the 
subjective nature of these symptoms they cannot be convincingly ascertained in animals 
[27]. 
Several studies monitored the effects of acute administration of psychotic drugs (single 
injection), but nowadays it is accepted, that appropriate chronic models should generate 
animals with schizophrenic phenotype that mimics several aspect of the human 
psychiatric disorder with a high constructive, face and predictive validity. These models 
may be appropriate to examine the effects of chronic antipsychotic drug treatments, 
according to the human practice [28].  
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There are four main groups of chronic animal models for schizophrenia: 
pharmacological-, lesion-, environmental- and genetic models. Recently it is supported 
that single animal models cannot recreate the diversity and complexity of schizophrenia, 
but the combination of these different procedures may help to produce a more reliable 
animal model [18, 20].  
1.5.1 Environmental models 
There are many developmental models, which cause disorders of different brain 
structures. It seems that underlying process of the disease occurs in the early stages of 
neurodevelopment and manifests only later, during the developmental restructuring of 
the central nervous system. Prenatal immune challenge by a number of external factors 
(such as bacteria, viruses and other pathogens), prenatal protein deprivation, maternal 
malnutrition or stress during pregnancy related with the increased glucocorticosteroid 
levels during fetal development result in disturbed development of brain structures, and 
cause a number of behavioral changes related to schizophrenia, i.e. reduced social 
interaction, impaired novel object recognition and disrupted PPI [29, 30]. 
The profound neurobiological effects of stress at postnatal life are believed to be the 
basis of many neuropsychiatric changes too. Since Hatch and colleagues first reported 
behavioral abnormalities in socially isolated rats [31], a large body of evidence has 
accumulated to suggest that postweaning social isolation has profound, long-term 
effects on rodent brain and behavior [32-37] [30]. Therefore, social isolation is an 
alternative, non-pharmacological model of schizophrenia that produces a number of 
behavioral consequences in adulthood that are similar to schizophrenia symptoms, 
including deficits in sensorimotor gating, pain sensitivity, motor activity, impaired 
novel object recognition and enhanced sensitivity to psychoactive drugs. This 
intervention causes reduced size and deficits in the prefrontal cortex, significant 
neurotransmission abnormalities including enhanced dopamine functions in the basal 
ganglia [4, 38, 39], and may generate a number of structural changes in the 
hippocampus, such as reduced length and density of dendrites in pyramidal cells and 
reduced number of newly formed neurons [30]. 
1.5.2 Genetic models 
As mentioned above, many genes are implicated in schizophrenia, therefore it is 
difficult to generate animal models that have similarly complex genotype. Since about 
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two decade, researchers have tried to create various gene knockout (KO) mice, which 
simulate some symptoms of schizophrenia. The dopamine transporter knockout mutant 
mouse fits with the DA hypothesis of schizophrenia, having deficits in sensorimotor 
gating and spatial cognitive function [16, 18]. The neuregulin-1 knockdown mouse is 
deficient in NMDA receptor expression showing several behavioral abnormalities such 
as hyperlocomotion, increased stereotype and impaired social interactions [18, 40]. In 
brains of schizophrenic patients reduced level of reelin was observed, which is a 
glycoprotein, that helps to regulate processes of neuronal migration and positioning in 
the developing brain by controlling cell–cell interactions, therefore it may play a role in 
the pathogenesis of the illness [40]. Deletion of its gene in mice results in widespread 
abnormalities throughout the brain, which are similar to the observed cytoarchitectural 
abnormalities in schizophrenia [16, 18]. However, knocking out of one gene does not 
lead to the ideal model, because it usually cannot reproduce all of the symptoms of the 
disease by itself. 
Animal models generated by artificial selection may also be important tools to gain a 
better understanding of the genetic makeup behind the complex symptomatology of 
different syndromes including schizophrenia [41-43]. Selective breeding is a method in 
which the experimenter selects a specific sign of a special disease and breeds only those 
animals that exhibit high degree of that trait. Therefore, selective breeding can produce 
animals that are of a higher risk of certain disorders with genetic background. Several 
studies used the selective-breeding procedures to develop new lines (or strains) of rats 
in psychiatric disorders such as epilepsy, depression or schizophrenia. Schwabe et al. 
have shown that a PPI-deficit can be selectively bred in Wistar rats and is already stable 
in the second filial generation [5]. Cognitive abilities also show a significant 
inheritance, as indicated by earlier experiments in selectively bred rats [44]. 
1.5.3 Lesion induced models 
Lesion models may also contribute to understanding the pathophysiology and 
neurodevelopmental functions of various brain regions in relation with schizophrenia. 
Lesions in the hippocampus, frontal cortex, dorsolateral prefrontal cortex or medial 
prefrontal cortex have been used to create structural models of psychosis in animals [16, 
18].  
9 
 
 
 
1.5.4 Pharmacological interventions 
A huge amount of drugs acting on different receptor systems (e.g. DA agonists, DA 
reuptake inhibitors, serotonin agonist) are used to develop a pharmacology model of 
schizophrenia [45]. 
1.5.4.1 NMDA receptor antagonists 
As discussed above, the NMDA receptor is a key factor in promoting glutamatergic 
neuronal activity throughout and plays a crucial role in brain plasticity especially during 
early development by affecting on several transmitter systems in the cortico-limbic-
striatal network [46, 47]. Therefore, the developing brain is highly susceptible to a 
chronic, low-dose blockade of NMDA receptors: it causes synaptic weakening and 
elimination in several brain regions, including the prefrontal cortex and the 
hippocampus [48-54]. Thus NMDA receptor antagonists (e.g. ketamine, phencyclidine, 
MK-801) worsen symptoms in schizophrenia or can induce schizophrenia-like 
symptoms in normal individuals [45, 55, 56]. Ketamine, a phencyclidine hydrochloride 
derivative and a noncompetitive NMDA receptor antagonist, is able to induce positive 
and negative symptoms in healthy humans similar to those associated with 
schizophrenia, including illusions, thought disorder and delusions, blunted emotional 
responses, emotional detachment, and psychomotor retardation [46, 57]. Animals 
treated with NMDA receptor antagonists also exhibit a number of changes related to 
schizophrenia, including deficits in cognitive behavioral tasks, in prepulse inhibition, as 
well as hyper-responsiveness to stimulants such as amphetamine [18, 20, 46, 58, 59].  
1.5.4.2 Drugs acting on transient receptor potential vanilloid 1 receptors 
Some evidence suggest that capsaicin desensitization or the lack of transient receptor 
potential vanilloid 1 (TRPV1) receptors can lead to different behavioral changes, some 
of which are related to schizophrenia, but investigations into these effects have been 
scarce [60-62]. TRPV1 receptor was discovered in 1997 and its presence has been 
indicated throughout the central nervous system (CNS) [63-69]. TRPV1-mediated 
activity was detected in different brain structures including hypothalamus, 
hippocampus, basal ganglia and cerebral cortex, albeit at much lower levels than in the 
dorsal root ganglia [70-75]. In addition to neurons, TRPV1 is expressed in the 
microglia, astrocytes and pericytes, too [65]. Capsaicin, the major pungent ingredient of 
hot peppers, derived from the plant genus Capsicum, and resiniferatoxin (RTX), derived 
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from Euphorbia resinifera, are known to activate TRPV1 receptors selectively, and 
their administration in high doses leads to the extensive degeneration in the areas 
innervated by primary sensory neurons (mainly the non-myelinated C-fibers) [76-78]. 
However, neonatal capsaicin administration did not change the density of TRPVR1 
receptors in most brain areas, which might explain why vanilloid-responsive cells in the 
CNS remained largely overlooked [64]. Yet, the extensive distribution of TRPV1 
receptors in the brain suggested that this receptor could play a significant role in the 
CNS, too.  It is proposed that TRPV1 receptors may take part in the pathogenesis of a 
range of disorders as diverse as Parkinson’s and Alzheimer’s disease, depression, 
anxiety and schizophrenia [22, 23, 61, 79-82]. Of particular relevance to schizophrenia 
was the observation that many dopaminergic cells in the mesencephalon are TRPV1-
immunopositive [64, 83]. Intranigral injection of capsaicin or treatment of rat 
mesencephalic cultures with capsaicin resulted in cell death of dopaminergic neurons 
[72], while the activation of TRPV1 receptors in the midbrain ventral tegmentum 
transiently increased dopamine release in the nucleus accumbens (NAcc) [84]. The data 
suggest a tonic facilitation of glutamate release exerted through TRPV1 activation by 
endovanilloids, including anandamide in the substantia nigra [85]. Only a few studies 
have investigated capsaicin desensitization as a method for schizophrenic models [60-
62]. These studies suggest that neonatal capsaicin treatment of rats produces 
hyperactivity and several brain changes (such as smaller cross-sectional areas, larger 
ventricles and aqueduct, smaller hippocampal area and reduced corpus callosum 
thickness) which are similar to those found in brains of schizophrenic patients [61]. In 
contrast, the capsaicin treatment of adult rats caused decreased locomotion and 
increased social interaction [62]. 
1.6 Complex models 
A few studies applied “double hit” method, i.e. certain combinations of the above 
mentioned models to investigate the hypothesis that these manipulations can enhance 
the reliability of the schizophrenia model [16, 86-88]. One of the most popular methods 
is the gene-enviromental interactions, including ventral hippocampal lesion with social 
isolation which produced an additive effect on locomotor activity and morphological 
changes in the prefrontal cortex and NAcc [89, 90]. Neonatal immune activator, 
polyinosinic-polycytidylic acid (polyI: C), treatment as an environmental factor in 
DISC1 transgenic mice results in a synergistic effect in the deficits of short-term 
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memory after puberty, although polyI: C treatment or DN-DISC1 expression by itself 
has little influence on wild type mice [91]. The subchronic NMDA-receptor antagonist 
treatment together with social isolation in adult or juvenile rats induced several 
behavioral abnormalities, such as hyperresponsiveness to different stress situations, 
drugs and altered pain sensitivity [37, 88, 92-94]. Importantly, combining the two 
manipulations did not produce detectable additive or synergistic effects on behavior, 
however, these animals showed more schizophrenia-like signs.  
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2. Aims of study 
 
1. Gene-environment interactions have important role in the development of 
psychiatric disorders. The first goal of the thesis was to generate a new substrain 
of rats with signs related to schizophrenia by combining three factors i.e. 
selective breeding after postweaning, social isolation and chronic ketamine 
treatment through several generations.  
2. The second aim was to characterize behavioral profiles (sensory gating, pain 
sensitivity, memory function and motor activity) of four experimental groups to 
reveal whether the selective breeding or the complex treatment plays a major 
role in the observed changes: naive socialized rats without any treatment 
(NaNo), or with isolation and ketamine treatment (NaTr) and the 15
th
 generation 
of selectively bred animals without any treatment (SelNo), or with isolation and 
ketamine treatment (SelTr).  
3. Given that there is some evidence to suggest that schizophrenia might be 
connected with TRPV1 receptor disturbances, we assumed that juvenile 
capsaicin desensitization might produce significant changes in behavioral 
profiles related to schizophrenia. Thus, the third aim of the thesis was to 
investigate the effects of juvenile desensitization on behavioral parameters 
impaired in schizophrenia, such as sensory-motor gating, motor activity and 
memory function, besides  demonstrating the effects on functions proven to be 
affected by TRPV1 receptor systems, i.e. pain sensitivity and urinary bladder 
function. 
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3. Materials and Methods 
3.1 Animals 
After institutional ethical approval was obtained from the Animal Care Committee of 
the University of Szeged, Wistar rats were used for the experiments. The animal 
housing rooms, as well as the experimental rooms, were kept under standard laboratory 
conditions (light-dark circle: 12:12 h; light on at 06:00 h; temperature 22  1 
o
C; 
relative humidity: 55  10 %). Inside the cages wood shavings were placed as bedding 
and nesting material, commercial rat diet and bottled tap water were available ad 
libitum. The cages were placed in shared racks so that auditory and olfactory contacts 
were maintained. The body weight of the animals was determined weekly during the 
whole study. 
3.2 Drugs 
The drugs employed were capsaicin (Plantakem Kft, Sándorfalva, Hungary), ketamine 
hydrochloride (Calypsol, Richter Gedeon Rt., Budapest, Hungary), xylazine 
hydrochloride (Rompun, Bayer, Leverkusen, Germany), gentamycin (Sanofi-Aventis, 
Budapest, Hungary), dexmedetomidine hydrochloride (Orion-Pharmos Pharmaceuticals 
Turku, Finland), λ-carrageenan (Sigma-Aldrich Kft., Budapest, Hungary) and morphine 
hydrochloride (Teva Zrt, Debrecen, Hungary). Capsaicin was dissolved in 10% Tween 
and 10% ethanol and further diluted with saline. All the other drugs were dissolved in 
saline. For desensitization the volume for subcutaneous (s.c.) injection was 0.2 ml/100 g 
body weight (except on day 4, 0.4 ml/100 g).  
3.3 Selective breeding process 
Starting from a population of outbred Wistar rats (‘parental generation’: 10 males and 
10 females), a breeding line was established by selective breeding according to the rats 
sensitivity to acute heat pain after social isolation and ketamine treatment. In further 
generations, the parental generation consisted of between 13-16 animals of each sex. 
The paradigm for selective breeding through several generations was as follows:  rats, 
after weaning at 3 weeks of age (21–23 days) were tested by measuring the pain 
threshold (tail-flick test, TF) and then housed individually for 28 days (between 4-7 
weeks of age), to develop social isolation, in cages of 42 × 15 × 18 cm (l × w × h). The 
animals were treated with ketamine 30 mg/kg intraperitoneally, 4 ml/1000 g body 
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weight, daily, 5 times/week, 15 injections in total) from 5 to 7 weeks of age. Duration of 
ketamine treatment and isolation parameters were adapted from earlier studies [88, 94, 
95]. At the end of the treatment, animals were re-housed in a group setting (4-5 rats per 
cage) and had 1 week of recovery, with no treatment afterwards. Behavioral assessment 
started at the age of 9 weeks with the TF test. Five rats of both sexes, that showed the 
highest pain threshold, as indicated by the TF latencies, were selected for the next 
breeding generation. Their offspring (1
st
 generation) and the subsequent 2
nd
 generation 
were also tested only in the TF test, and again 5 rats of each sex with the highest pain 
thresholds were chosen as parents of the next generation of the breeding line. From the 
3
rd
 generation we also investigated sensory gating by prepulse inhibition (PPI)  test (at 
the age of 10 weeks), and the animals showing a high pain threshold, along with a low 
PPI were selected for a further breeding line. From the 6
th
 generation, recall memory 
functions and motor activity by applying the novel object recognition test (NOR) were 
also observed (at the age of 11 weeks). Thus, animals with impaired pain sensitivity, 
sensory gating and memory were selected for the further breeding lines. From the 
second generation, 5-7 animals of both sexes were selected for breeding. Sibling mating 
was avoided by paying close attention to the litter of origin, and the litter size was 
reduced to a maximum of 6-8 pups (the number of males and females was 
approximately equal), ensuring that each family contributed equally to the next 
generation. We found no signs of inbreeding depression (i.e. reduction of fertility, 
deformed offspring, small litters, poor mothering ability) in the selected line. Male rats 
of the 15
th
 generation were involved in the present experiment.  
3.4 Capsaicin desensitization process 
 In four series of experiments after weaning (designated as the first day of the 
experiment) male Wistar rats were treated on four consecutive days with increasing 
doses of capsaicin (10, 20, 50 and 100 mg/kg s.c.) or its vehicle. Since desensitizing 
doses of capsaicin cause excessive pain and discomfort, administration was done under 
ketamine-xylazine (72 and 8 mg/kg intraperitoneally, respectively) anesthesia. The age 
of the animals used for behavioral experiments was between 2 and 3 months.  
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3.5 Behavioral tests 
3.5.1 Wiping test 
Ocular application of capsaicin (1 drop 0.001 % capsaicin) into one of the eyes was 
done with a pipette, and the animals were observed for the number of front paw eye 
wipes and blepharospasm for 30 sec. The test was performed at least 5 weeks after the 
capsaicin desensitization. 
3.5.2 Ultrasound examination of the urinary bladder 
The method was based on our earlier study [96]. The rats were anesthetized with 
dexmedetomidine (150 µg/kg s.c.), which has long-lasting hypnotic anesthetic effects; 
furthermore, it produces diuresis and overflow incontinence which allows the 
ultrasound examination of the urinary bladder. We used sonography (7.5 MHz linear 
passed array transducer; Hitachi EUB 405), and the bladder volume was estimated by 
substituting the diameters into the ellipsoid equation formula: V= a x b x c x π/6, where 
a, b and c are the lengths of each major axis. Since bladder volume increases 
significantly with body weight [96], we corrected the volume (ml) for 100 g body 
weight accordingly:  relative bladder volume (RV) = (bladder volume x 100)/(body 
weight). Bladder volume was assessed when the first urine drop appeared, and two more 
times with 30 minute intervals.  
3.5.3 Acute heat pain sensitivity  
Acute nociceptive threshold was assessed by the TF test. During the test, the rats were 
wrapped in a towel and held firmly to prevent too much movement, but gently enough 
to minimize stress. The reaction time was determined by immersing the distal 5 cm 
portion of the tail in hot water (46, 48 and 52 °C in capsaicin model and 48 °C in the 
complex model) until a tail-withdrawal response was observed (cut-off time: 40, 20  and 
10 s respectively). TF latencies were obtained three times in the capsaicin and four 
times in the complex model at 0, 30, 60, and 90 min and, were averaged to establish the 
pain threshold for each group. 
3.5.4 Assessment of mechanical and thermal sensitivity in inflammatory 
pain model 
Mechanical and thermal sensitivities were recorded in the same testing box (11 x 17 x 
20 cm). 
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Mechanical sensitivity was assessed with a Dynamic Plantar Aesthesiometer (automatic 
von Frey test (VF); Ugo Basile, Italy). Measurements were done with a straight metal 
filament that exerts an increasing upward force at a constant rate (4.25 g/s) with a 
maximum cut-off force of 50 g (cut off time 8 s). The filament was placed under the 
plantar surface of the hind paw and used through a mesh base. Measurement was 
stopped when the paw was withdrawn, and results were expressed as paw withdrawal 
thresholds in grams.  
To determine the heat pain threshold, the paw-withdrawal test (PWD) was used [97]. 
Heat stimulation was applied to plantar surface of the hind paw. The time until the 
withdrawal of the tested paw was measured and cut-off time was set at 20 s to avoid 
tissue damage. 
After a habituation period (at least 20 min) the baseline pain thresholds were detected (-
180 min) and then unilateral inflammation was induced by intraarticular injection of 
carrageenan (300 µg / 30 µl) into the right ankle joint (0 min) [98]. Measurements were 
repeated 3 hours after the carrageenan injection, then the animals were treated with 3 
mg/kg morphine s.c., and the mechanical and thermal nociceptive thresholds were 
determined at 30-min intervals for 90 min. 
3.5.5  Prepulse inhibition test 
PPI of the acoustic startle response was measured in a plexiglas startle chamber, which 
was divided into four identical compartments (12 x 17 x 15.3 cm) in a sound-attenuated 
room. Noise bursts were applied through a speaker mounted close to the backside of the 
chamber. Under the cage, a piezoelectric accelerometer (i.e. force transducer) sensitive 
to rat startle-like movements produced an electrical signal that was amplified by a signal 
conditioner and visualized on a computer screen. Rats were allowed to habituate to the 
background noise (70 dB) for 10 minutes, immediately thereafter they were exposed to 
three different trial types: a PULSE ALONE (PA) in which a 40 ms 95 dB white noise 
burst was presented; PREPULSE ALONE (PPA), 20 ms 76 dB; and the PREPULSE-
PULSE PAIR (PP) in which prepulse stimuli were followed by the acoustic startle 
stimulus with a latency of 150 ms. All types were presented 10 times. The interstimulus 
intervals ranged from 7 s to 13 s, and there was a 10 minute resting period between each 
trial. %PPI values were calculated as percentages using the following formula: 
%PPI = [1 − (startle response for PP trial) / (startle response for PA trial)] × 100. 
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Since the startle reaction increases significantly with body weight, we normalized the 
reaction to body weight, accordingly: 
Relative startle reaction: (startle reaction x 100)/(body weight (g)). 
3.5.6 Novel object recognition test 
NOR test is used to evaluate cognition, particularly recall memory, in both animal 
models. It was conducted in a plexiglas box (60 x 34 x 33 cm) without bedding. Toy 
brick towers (Lego Group, Billund, Denmark) with similar size (8 x 2 x 3 cm) were 
used as test objects. They were affixed to the floor of the box with play-doh to prevent 
the objects from being displaced during testing. The objects had no natural significance 
for the rats, and previous pilot work showed no preference for either object used. The 
objects were placed 13 cm from the opposing corners in the arena, and the rat was 
consistently placed in the middle of the arena to be equidistant from both objects. The 
rats were habituated to the testing room for 60 minutes prior to the start of experiments. 
Between the testing of different animals, the arena and the objects were cleaned with 
70% ethanol. 
Habituation phase: During a single 10 minute session, each rat was placed in the 
center of the chamber and allowed to explore the open field without any objects.  
Sample phase: One minute after the habituation session, the sample phase began. Two 
objects with the same size and shape (S1 and S2) were mounted in the open field. Rats 
were placed again into the center of the open field, and allowed to explore the two 
objects for 5 minutes.  
Test phase: At the end of the sample phase, each rat returned to their home cage for an 
hour interphase interval, while one of the objects was replaced with another, visually 
non-identical one (N: novel). The other object (F: familiar) was the same as in the 
sample phase. Afterwards, a 5-minute test phase followed. 
Behavior was scored online without video device in the capsaicin model, but in the  
complex model we used an infrared video device (WCM-21VF, CNB, China). The 
following parameters were scored in each phase: duration or frequency of occurrence of 
stereotypic behaviors (rearing, self-grooming), the time of exploratory activity, walking 
and inactivity. Object exploration was defined as licking, sniffing or touching the object 
with the forepaws, but not leaning against, turning around, standing on or sitting on the 
object. Since the habituation phase lasted twice as long as the other phases, behavioral 
activity was divided into and scored in sub-phases (0-5 and 5-10 min) for analysis. 
18 
 
 
 
The discrimination index (DI) was calculated for both the sample and test phases as 
follows: DI: (time spent exploring N vs S1 object − time spent exploring F vs S2 object) 
/ (total time spent exploring both the objects [S1+S2] vs [N+F]). If the animals did not 
explore the objects during the sample or test phases, they were considered as non-
responders and data from these animals were not included in the final analysis 
(altogether one animal from the SelTr group was excluded on such grounds). The 
scoring of the different behaviors was carried out by investigators blind to the applied 
treatment. 
3.5.7 Telemetry  
This method is appropriate to monitor gross locomotor acitivity in freely moving 
animals (Respironics, Mini Mitter, Vitalview, Oregon, USA). Animals were 
peritoneally implanted with Minimitter transmitters (E-Mitter, Philips Respironics ) 
under ketamine-xylazine anesthesia. A small lower abdominal incision was made and a 
sterilized probe was inserted into the peritoneal cavity. Following the surgery the 
animals received antibiotic treatment (13 mg/kg gentamycin, s.c.) to prevent infection. 
After a one-week recovery period the animals were housed individually in cages 
measuring 42 x 30 x 18 cm, and standard laboratory chow and tap water were available 
ad libitum. The cages were placed on receiver platforms (ER-4000 Energizer Receiver) 
in an isolated room maintained under standard laboratory conditions. Motor activity was 
monitored continuously for 5 days without any disturbance.  
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3.6 Protocols 
3.6.1 Experimental paradigm of the complex model 
Four experimental groups of male rats were compared: naive socialized rats without any 
treatment (NaNo), or with isolation and ketamine treatment (NaTr) and 15
th
 generation 
selectively bred animals without any treatment (SelNo), or with isolation and ketamine 
treatment (SelTr). Groups were matched according to body weight (50 ± 1.7 g) and their 
TF values at the age of 3 weeks. The testing schedule is presented in Table 1. 
 
 
 
Table 1. Experimental paradigm of complex model TF: tail-flick test; PPI: prepulse inhibition test; NOR: 
novel object recognition test; NaNo: naive animals without treatments; NaTr: naive animals with social 
isolation and ketamine treatment; SelNo: selectively bred rats without treatments; SelTr: selectively bred 
rats with social isolation and ketamine treatment; SI: social isolation; KET: ketamine treatment. 
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3.6.2 Experimental paradigm of capsaicin model 
Four experimental series of rats were tested with two sub-groups within the series: 
control animals received vehicle and the second group were treated with capsaicin. 
In the first series the TF, PWD, VF and ultrasound examination were performed, in the 
second the telemetry test, in the third series the NOR test was involved and in the fourth 
series the PPI test was carried out (Table 2.). All of the animals were involved in the 
wiping test to check the desensitization. 
 
Type of tests Treatment 
Number of 
animals 
Age at test 
(week) 
Series 
Tail-Flick 
Capsaicin 11 
9 1 
Vehicle 8 
Paw withdrawal 
Capsaicin 11 
9 1 
Vehicle 8 
von Frey 
Capsaicin 11 
10 1 
Vehicle 8 
Ultrasound 
Capsaicin 11 
12 1 
Vehicle 8 
Telemetry 
Capsaicin 8 
10-14 2 
Vehicle 7 
Novel object 
recognition 
Capsaicin 5 
7 3 
Vehicle 7 
Prepulse 
inhibition 
Capsaicin 10 
12 4 
        Vehicle 8 
 
Table 2. Experimental paradigm of capsaicin model 
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3.7 Statistical analysis 
Data are expressed as means ± SEM. Data were assessed using one- and two-way 
ANOVA with repeated measures and the Fisher-LSD post hoc test. A p-value less than 
0.05 was considered significant. For the analyzes, STATISTICA 11 software (Statsoft 
Inc.,Tulsa, OK, USA) was used. 
In the complex model the median split method was used for transforming continuous 
variables into categorical ones. A quartile-based scoring method was used. The values 
in the first (lower) quartile received 0 points, values in the third (upper) quartile 
received a score of 2, and the values between them received 1 point. Five aspects (TF 
latency at the age of 9 weeks, relative startle reaction, %PPI, DI and grooming activity) 
were rated from 0 (lowest risk) to 2 (highest risk), and summarized to generate the total 
schizophrenia score, which ranged from 0-10. Using this score, it was possible to 
classify animals as either low- or high-risk for schizophrenia using quartiles of the total 
schizophrenia score.  
Sampling frequency regarding general motor activity in telemetry, data was set to 1 min 
throughout the experiment and one-hour average of the data was analyzed. 
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4. Results 
4.1 Body weight 
The body weight of animals in the complex model measured on the different testing 
days (Fig. 3.) showed a significant effect of time (F3,117 = 3077.81, p< 0.0001) and strain 
(F1,39 = 24.78, p< 0.001), and the interaction between time and strain (F3,117 = 7.13, p< 
0.001) was also significant. That is, the substrain started to exhibit a lower body weight 
from age of 9 weeks. The social isolation together with ketamine treatment did not 
result in further weight loss. 
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Figure 3. The body weight measured on the day of different behavioral tests in the complex model. * 
indicates significant differences between the naive and selected groups. Data are expressed as means ± 
SEM. 
 
 All of the animals survived capsaicin desensitization with this dose regimen, suggesting 
that this method is non-lethal for juvenile animals. The ANOVA of body weight 
revealed a significant effect of time, but not for treatment, thus capsaicin-treated 
animals had similar body weight as the control ones (Fig. 4.).  
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Figure 4. The body weight at capsaicin model. Data are expressed as means ± SEM. 
4.2 Wiping test and urinary bladder function 
We performed the wiping test and measured the urinary bladder to verify the effect of 
capsaicin desensitization. Regarding the effects of the capsaicin eye drop, it produced 
blepharospasm and violent wipes of the eye in control, but not in the capsaicin-treated 
animals, confirming desensitization (Fig. 5.). 
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Figure 5. Wiping test. Data are expressed as means ± SEM. The symbol * denotes significant differences 
from capsaicin group.  
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The first urine drop appeared about 20 min after the dexmedetomidine administration. 
Urine dribbling was observed almost continuously, suggesting a continuous overfilling 
of the bladder. As for the effect of capsaicin desensitization on bladder capacity, 
ANOVA with repeated measures revealed a significant effect of treatment (F1,17 = 8.8; 
p < 0.01) and time (F2,34 = 4.6; p < 0.05), thus capsaicin treated animals had larger 
bladder volumes compared to the control group (Fig. 6.). 
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Figure 6. Relative urinary bladder volume determined by ultrasound examination at the beginning of 
urine dribbling (0 min), 30 and 60 min later. Data are presented as means ± SEM. The symbol * denotes 
significant differences from control group. 
4.3  Pain sensitivity 
4.3.1 Tail-flick test 
Regarding the selectively bred animals, ANOVA revealed a significant effect of strain 
(F1,39 = 4.23, p< 0.05), time (F1,39= 328.15; p<0.001) and significant interaction (F1,39= 
4.94; p<0.05) on the TF latencies measured at 3 and 9 weeks of age; thus, the TF 
latency significantly increased in all groups with time. Post-hoc comparison did not 
reveal differences between the groups at the age of 3 weeks, but a tendency towards TF 
latency increase was observed in the new substrain (naive: 4.1 0.21 s 15
th
 generation. 
4.6 0.27 s). Significant differences were observed at the age of 9 weeks between NaNo 
and both of the substrain groups (SelNo and SelTr), with these groups having the lowest 
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pain sensitivity (Fig. 7.). The latency in the NaTr group did not differ from any other 
group. 
 
Figure 7. Tail-flick latency at the age of 3 and 9 weeks in the complex model. Data are expressed as 
means ± SEM. The symbols indicate significant differences between time points (+) and compared to the 
naive non-treated (NaNo) group (*). 
 
As regards the capsaicin treated series, two-way ANOVA revealed a significant effect 
of temperature (F2,34 = 103, p< 0.001), but not of capsaicin treatment (Fig. 8.); thus, the 
acute-heat pain sensitivity increased by temperature, but was not influenced by 
capsaicin desensitization. 
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Figure 8 . Tail-flick latencies at different water temperatures in the capsaicin model. Data are presented 
as means ± SEM. The symbols indicate significant differences between time points (+). 
 
4.3.2 Mechanical and thermal pain sensitivity in inflammatory pain model 
The baseline of von Frey and PWD test did not differ significantly in the capsaicin and 
control groups on pain sensitivity (Fig. 9.). 
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Figure 9. Mechanical (A,B) and thermal (C,D) pain thresholds before (− 180 min) and after (0 min) 
carrageenan administration, and the effect of morphine (3 mg/kg, s.c.) on the inflamed (A,C) and non-
inflamed (B,D) sides. Data are presented as means ± SEM. The symbols denote significant differences: * 
from control group, +: from pre- and # from post-carrageenan values. 
 
Regarding the threshold for mechanical allodynia, significant effects of treatment 
(F1,35 =  =11.0, p < 0.005), side (F1,35 = 90.2; p < 0.001), time (F4,140 = 50.6; p < 0.001) 
and their interactions were observed. Post- hoc comparison revealed that juvenile 
capsaicin desensitization resulted in a slightly decreased mechanical allodynia 
(p = 0.13), while the anti-allodynic effect of morphine was significantly prolonged in 
desensitized animals (Fig. 9.A). On the non-inflamed side, significant increases in the 
withdrawal threshold were observed in both groups after morphine administration 
(Fig. 9.B). 
In the case of thermal hyperalgesia, significant effect of treatment (F1,35 =  =19.0, 
p < 0.001), side (F1,35 = 14.8; p < 0.001), time (F4,130 = 31.4; p < 0.001) and their 
interactions were observed. Carrageenan resulted in a similar degree of thermal 
hyperalgesia in both groups. Morphine caused a significant increase in PWD latency on 
the inflamed side with a more prolonged effect in the desensitized group (Fig. 9.C). 
A 
C D 
B 
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Furthermore, morphine caused a significant increase in the nociceptive threshold on the 
non-inflamed paw in the capsaicin-pretreated animals (Fig. 9.D). 
4.4  Sensory gating 
ANOVA revealed a significant effect of prepulse stimulation (F 1,39 = 72.47, p < 
0.0001), and strain (F 1,39 = 6.50, p < 0.05) (data are not show) on the magnitude of the 
startle reaction in the complex model. The response significantly decreased in the case 
of prepulse stimulation in all groups, except the SelNo group. The post hoc comparison 
revealed significant differences between the NaNo and SelTr groups with the PA, while 
both of the selectively bred groups showed a significantly higher degree of relative 
startle reaction compared to both of the naive groups with the PP (data are not shown). 
Regarding the sensory gating, the effect of strain was significant (F3,39= 5.59; p<0.005); 
thus, both groups of the substrain (SelNo and SelTr) had lower %PPI compared to the 
naive groups (NaNo and NaTr) (Fig. 10.). 
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Figure 10. %PPI values in the different groups of complex model. Data are expressed as means ± SEM. * 
and o indicate significant difference compared to the naive non-treated (NaNo) and treated (NaTr) groups, 
respectively.  
 
In the capsaicin animal model, repeated measures ANOVA of the relative startle 
reaction revealed a significant effect of prepulse stimuli (F1,16 = 68.95, p = 0.001), but 
not of treatment. Capsaicin-treated animals showed similar startle reflex amplitude 
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elicited by PA or PP compared to the control group; the response amplitude 
significantly decreased in both groups with PP (data are not show). Therefore, the %PPI 
did not show significant differences between the two groups (Fig.11.). 
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Figure 11. %PPI values in the different groups of capsaicin model. Data are presented as means ± SEM. 
4.5 Motor behavior 
Regarding the motor behavior during NOR test in the complex model ANOVA revealed 
a significant effect of strain (F1,39=6.75, p<0.05), phase (F3,117=27.35, p<=0.001), and 
interaction between phase and strain (F3,117=3.69, p<0.05) on the rearing activity (Fig. 
12.A). Rearing activity decreased with time (phase) in all groups, and the 15
th
 
generation showed lower rearing activity in the sample and testing phases. The NaTr 
group showed enhanced rearing activity in the test phase compared to all the other 
groups. 
Strain differences were also found in the grooming behavior, i.e. the substrain showed 
increased grooming activity during the second part (5-10 min) of the habituation phase 
(F1,39=4.18, p<0.05; Fig. 12.B).  
Analysis of walking duration revealed a significant effect of strain (F1,39=8.88, p<0.01), 
phase (F3,117=56.61, p<0.001) and a phase-treatment interaction (F3,117=3.39, p<0.05); 
thus, walking activity decreased with time (phase), and was lower in the new substrain, 
while the NaTr group showed enhanced activity in the sample and test phases (Fig. 
12.C). 
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Figure 12. Rearing (A), grooming (B), and walking (C) activities in the different phases of the NOR test 
in the complex model. + and # indicate significant difference from the first (0-5 min) and second (5-10 
min) habituation period respectively; x and * sign significant difference with treatment and strain 
respectively.  
 
No significant differences were observed in any types of motor behavior (e.g. rearing, 
grooming) and inactivity in any phases between the two groups in the capsaicin model 
(data are not shown). 
Regarding the analysis of the telemetric data, motor activity showed a daily rhythm with 
night maxima and day minima in the control and capsaicin desensitized animals. The 
separate analysis of dark and light phases showed a significant effect of treatment 
(F1,62 = 5.87, p < 0.05) and a close to significant effect of phase (F1,62 = 3.56, p = 0.06;), 
which is to say that the desensitized animals exhibited enhanced motor activity during 
the active phase compared to control rats (Fig. 13.). 
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Figure 13. Mean motor activity during dark and light periods. Data are presented as means ± SEM. The 
symbol * indicates significant differences between the two groups.  
4.6 Memory functions in novel object recognition test 
Both NaTr and SelTr groups showed an increased exploring time of the objects (Fig. 
14.A). As for the DI, ANOVA revealed a significant effect of phase (F1,38=5.70, 
p<0.05). The post hoc comparison revealed that in the NaNo group DI was significantly 
enhanced in the presence of the new object, while this enhancement could not be 
observed in any other groups (Fig. 14.B)  
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Figure 14. Exploratory (A) activities in the different phases of the NOR test. (B): Differentiation index in 
the sample and test phases. + indicates significant difference between the phases. Data are expressed as 
means ± SEM. 
 
In the sample phase, no significant differences were observed in the time spent 
exploring the two identical objects between the groups in the capsaicin model 
(Fig.15.A.). In the test phase, the time of the novel object exploration was significantly 
longer than that of the familiar one in control animals (p < 0.01), while this difference 
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was not significant in the desensitized group. As regards the DI significant increase was 
observed in both groups of capsaicin series (Fig.15.B.). 
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Figure 15. Object exploratory activity (A) and differentiation index (B) in the sample and test phases of 
NOR test. Data are presented as means ± SEM. + indicates significant difference between the phases and 
# indicates significant differences in the exploration time between the familiar and novel objects.  
4.7 Categorization 
ANOVA revealed significant differences between the four groups (F3,39=9.47, p<0.001) 
in the summarized score of the different groups, i.e. the NaNo group had the lowest 
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score, while the SelTr group scored the highest (Fig. 16.A). The histogram of the 
summarized score shows that all NaNo animals scored lower than 6 points, while in all 
of the other groups there were some animals that scored higher, and the highest ratio of 
these was observed in the SelTr group (Fig. 16.B). 
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Figure 16. 
Means ± SEM (A) and the distribution (B) of the summarized score within each group. The symbols * and 
x indicate significant differences compared to the naive non-treated (NaNo) and treated (NaTr) groups, 
respectively. 
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5. Discussion  
Schizophrenia poses a challenging degree of complexity with respect to genetic and 
environmental factors; nonetheless, only a few studies have addressed possible gene-
environment interactions in the context of schizophrenia models [91, 99, 100]. We 
found that combined selective breeding, postweaning social isolation and subchronic 
NMDA antagonist treatment caused permanent impairments in sensory gating, memory 
function, pain sensitivity and motor activity; the parameters that are disturbed in 
schizophrenia too. Our data suggest that this complex paradigm can lead to an improved 
model of schizophrenia; although, further breeding is required to enhance its reliability.  
On the other hand juvenile capsaicin desensitization caused long-lasting disturbances in 
different physiological processes related to C-fiber functioning; i.e. wiping response, 
morphine sensitivity and urinary bladder capacity. It also caused significant 
deterioration in memory function and motor activity under freely moving conditions, 
but no disturbances of the sensory gating were observed, suggesting that capsaicin 
desensitization by itself can lead to only few disturbances that might be related to 
schizophrenia. 
5.1 Sensory functions 
Clinical reports pointed out that many patients with schizophrenia are less sensitive to 
pain than other individuals, and this is likely associated with increased morbidity and 
mortality [28, 101, 102]. Data are available to suggest that juvenile isolation induces 
significant changes in pain sensitivity, which might be due, at least partially, to changes 
in the number and activity of opioid receptors; suggesting a high importance of housing 
conditions in schizophrenia models [34, 40, 88, 93, 94, 103-106]. Subchronic ketamine 
treatment and subsequent social isolation in adult rats produces slight changes in pain 
sensitivity [93]. Our previous study demonstrated that juvenile isolation, but not 
ketamine treatment, attenuated responses evoked by acute heat stimuli; while the 
combination of the two manipulations did not result in a further increase in TF latency 
[88]. These interventions alone and in combination enhanced the antinociceptive effect 
of morphine. While selective breeding led to a significant increase in pain threshold, the 
complex treatment applied in the present study did not result in a further enhancement; 
suggesting that genetic factors played a larger role in this effect. 
The current findings support earlier data which showed that both neonatal and adult 
capsaicin desensitization or KO of the TRPV1 receptors lead to an irreversible 
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suppression of wiping behavior in response to irritating chemical stimuli [107, 108]. 
The presence of persistent changes in wiping behavior of rats treated at the juvenile age 
provides behavioral verification of the efficiency of capsaicin treatment. 
Several studies showed that both neonatal and adult capsaicin desensitization resulted in 
decreased mechanical and/or thermal pain responses in different inflammatory models 
[109-111]. We did not observe significant alterations in acute and inflammatory pain 
sensitivities in desensitized animals, which is in agreement with some earlier data 
obtained in neonatal or adult desensitized rats [60, 112]. It is assumed that alterations in 
capsaicin-insensitive neurons and/or reorganization of the CNS may contribute to the 
normal pain sensitivities in capsaicin-treated animals [112, 113]. However, the 
antinociceptive effect of morphine was enhanced and prolonged during joint 
inflammation in both mechanical and thermal tests. Only one study investigated the 
antinociceptive property of morphine in inflammatory pain, which found that morphine 
caused a greater effect in the inflamed than in the non-inflamed paw in control rats, and 
this difference was absent in capsaicin-treated animals [114]. We found a similar 
phenomenon in our model, as well as a prolonged effect of morphine. Opioid receptor 
binding studies showed that the number of binding sites and binding affinity in the 
dorsal horn remained unaltered after adult capsaicin treatment, but were decreased by 
neonatal capsaicin exposure [115, 116]. The paradoxical finding that desensitization 
enhances the effects of morphine might be due to the decreased nociceptive input to 
dorsal horn neurons because of the absence of TRPV1-expressing afferent fibers.  
Sensory dysfunction was indicated by impairment of urinary bladder function as well. A 
considerable amount of evidence indicates that capsaicin-sensitive mechanisms regulate 
the micturition threshold by relaying information to the CNS about the volume of fluid 
present in the bladder [117-121]. Both neonatal and adult capsaicin treatments lead to 
an impairment of urinary bladder function, such as an increased threshold for 
micturition or a reduced frequency of micturition contractions [118, 122]. Furthermore, 
these interventions lead to increased bladder capacity detected by the cystometrographic 
method [118, 120].  Almost 20 years ago, a simple, noninvasive and reliable 
ultrasonographic method was described for the determination of urinary bladder 
capacity in anesthetized rats [96]. Our in vivo results revealed that the bladder capacity 
is significantly larger in juvenile desensitized rats compared to the control animals. 
Enhanced bladder volume was also observed 5 weeks after adult capsaicin 
desensitization in rats (RV: 0.3 0.016 and 0.44  0.019, control and desensitized 
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animals, respectively) [123]. Thus, capsaicin desensitization applied at any age results 
in enhanced bladder capacity, suggesting that sensory transmission in the micturition 
reflex depends on TRPV1 receptors at all stages of development.  
5.2 Sensory gating 
PPI is regulated by hippocampal, prefrontal, amygdaloid and basal ganglia regions, and 
the potential contribution of the pathological changes in these regions to PPI deficits in 
schizophrenia patients has been suggested [124-126]. 
Previous studies revealed that repeated NMDA-antagonist treatment of neonatal or adult 
rats led to the disruption of PPI in some but not all the animals [127-130], and the 
cessation of NMDA-antagonist treatment resulted in remission, suggesting that the 
treatment by itself is not sufficient to produce a long-lasting PPI disturbance [59, 131-
133]. Plenty of evidence suggest that long-term postweaning social isolation may also 
induce impaired PPI in rodents, but resocialization may lead to recovery; however, the 
data are somewhat inconsistent [4, 45, 134-140, 140-143]. It is assumed that changes in 
the prefrontal cortex after social isolation and/or imbalances between neural 
connections within the cortico-striato-limbic circuitry lead to the observed PPI 
disturbances [4]. Disturbed PPI as a result of selective breeding, was proven to be 
heritable, and this can be used to develop an animal model for schizophrenia [5, 144-
147]. The rats with impaired PPI also exhibited deteriorated social behavior, impaired 
reward responses, and abnormalities in information processing; which indicates that rats 
with low PPI show other schizophrenia-like disturbances, as well. Regarding the 
combination of genetic manipulation with environmental factors, it has been shown that 
postweaning social isolation for 12 weeks did not impair PPI in Nurr1 wild type mice, 
but it was disturbed in heterozygotic animals [148].  
We did not find a striking effect of social isolation and ketamine treatment on PPI after 
two weeks of treatment cessation in naive animals. Selective breeding was effective, but 
the combination of these interventions did not lead to further impairment; suggesting 
that genetic factors played the major role in the development of PPI disturbance. 
Only a few studies investigated the role of TRPV1 receptors in sensory gating with 
controversial results. It has been shown that cannabidiol (is a natural component of the 
marijuana plant) through the activation of TRPV1 receptors reversed the NMDA-
receptor antagonist-induced (MK-801) disruption of PPI in mice [149]. Neither 
capsazepine (TRPV1 receptor antagonist) nor acute or chronic cannabidiol affected PPI 
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by themselves, and capsazepine by itself did not influence the effect of MK-801 [149, 
150]. In contrast, a more recent study found disrupted PPI after cannabidiol 
administration in rats, but it had no effect on the MK-801-induced disruption of PPI 
[151].  The only one piece of literature regarding the effect of neonatal capsaicin 
desensitization on PPI supports our present finding that desensitization has no effect on 
PPI [152]. The ineffectivity of capsaicin desensitization or capsazepine per se on PPI 
suggests that TRPV1 receptors do not directly interfere with normal sensorimotor 
gating, but further studies are required to reveal the effects of capsaicin desensitization 
on PPI under different conditions.  
5.3 Cognitive function 
Our results show that the complex treatment and the capsaicin desensitization caused 
significant deterioration in memory function. Cognition, including memory, is impaired 
in schizophrenia, and both social deprivation and repeated treatment with NMDA 
antagonists of juvenile animals can disrupt memory functions, which are related 
primarily to the prefrontal cortex [46, 153-158]. However, several studies failed to 
induce impairments in tests of memory with these treatments, or only modest learning 
disturbances were observed [46, 49, 50, 59, 124, 129, 130, 156, 157, 159-161]. Ashby et 
al. investigated the effects of subchronic NMDA-antagonist, MK-801, and postweaning 
social isolation (for 5 weeks) on hippocampal long term potentiation (LTP) after a 7 
days’ washout period [87]. While subchronic MK-801 treatment enhanced hippocampal 
LTP, postweaning social isolation did not influence it, and the combination of the two 
manipulations did not result in detectable additive or synergistic effects on hippocampal 
plasticity. 
Ample data are available on the effects of activation or desensitization of TRPV1 
receptors on various CNS structures and functions, with inconsistent results. Exposure 
of central neurons to high doses of capsaicin triggers cell death or apoptosis, and the 
degeneration might be due to calcium release into the cells and the induction of 
proteases [69, 79, 162-164]. However, the majority of the neurons may be spared by the 
protective effect of exogenous nerve growth factors, and also markers that are 
associated with CNS neurons which are unchanged after neonatal capsaicin 
administration [64, 165]. We applied capsaicin desensitization at a young age that 
would be defined as early adolescence in human terms, when the development of the 
central and peripheral nervous system has not finished yet [166-168]. Earlier results 
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suggested that capsaicin-induced neurodegeneration in specific brain sites declines 
progressively during maturation [78]. It is well-known that during postnatal 
development sensory experiences play critical roles in the refinement of cortical 
connections, therefore, degeneration of central axons and terminals of peripheral 
sensory neurons lead to intrinsic somatosensory deprivation and, in turn, functional and 
structural alterations in the CNS. Furthermore, capsaicin treatment causes significant 
changes in substance P content and the number of muscarinic-, dopamine1-, serotonin-, 
and cannabinoid receptor binding sites [169, 170]. It seems that TRPV1 receptors 
comprise a neuromodulatory system in the brain, operated by endovanilloids. Since 
several endogenous cannabinoid lipids (e.g. anandamide, N-arachidonoyl-dopamine) 
can activate the TRPV1 receptors, it may be assumed that at least a part of their 
behavioral effects are due to the activation of these receptors [171-174]. Their activation 
causes anxiogenic behaviors, while their pharmacological blockade leads to anxiolytic 
effects and changes in fighting behavior [79, 175, 176]. The extensive reduction of 
afferent information together with the damage of the areas involved in memory 
processes should consequently bring out cognitive disorders after capsaicin 
desensitization. Several earlier studies suggested that TRPV1 receptors might play an 
important role in memory functions mainly at the hippocampal level, but the results are 
controversial [65, 79, 81, 177-179]. TRPV1 receptor activation can modify both LTP 
and long term depression (LTD) at the hippocampal level, and LTP is damaged in 
TRPV1-deficient mice [81, 178, 180]. Since both LTP and LTD are presumed to play a 
part in the establishment of stable memories, the manipulation of TRPV1 receptors can 
influence these processes [79, 181, 182]. It is supposed that capsaicin and endogenous 
lipids can potentiate the GABA-dependent depression in the CA1 region of the 
hippocampus, by the activation of presynaptic TRPV1 receptors in GABAergic 
hippocampal nerve terminals [183]. Furthermore, rats treated with high dose capsaicin 
as neonates had reduced hippocampal volume and cortical thickness and they exhibited 
signs of learning impairment [81, 184]. However, microinjections of low dose capsaicin 
into the dorsal hippocampus prevented acute stress induced memory impairments [185]. 
These data suggest that TRPV1 channels may be a potential target for protecting both 
hippocampal synaptic plasticity and spatial memory retrieval. 
The NOR task is based on the spontaneous novel object preference of rodents. A 
reduction in novel object recognition might be interpreted as a recall memory deficit, 
and the underlying process is a possible analogue of declarative memory in humans 
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[186-188]. Anatomically, this task is assumed to depend on the hippocampus, the 
nigrostriatal dopaminergic pathway and rhinal cortex [189, 190]. Both postweaning 
isolation and NMDA antagonist treatment can lead to impairment in the NOR test, but 
the results are controversial in this respect, too [48, 140, 157, 157, 191-195]. We have 
found impairment in the NOR test in treated animals of both the complex model and the 
desensitized group, i.e. the ability to discriminate between novel and familiar objects 
was disturbed; thus, we assume that both genetic, environmental and pharmacological  
factors play a role in the memory deficit. However, other memory test (e.g. T-maze or 
holeboard) also should be applied to characterize further memory deficits in detail.  
5.4 Motor activity 
Altered motor activity has been also reported in schizophrenia. Depending on the 
disease subtype, psychopathology and medication, excessive motor agitation, reduced 
motor activity, even akinetic episodes are observed [6, 196-200]. Both the dopaminergic 
and the glutamatergic systems in the prefrontal and subcortical areas are involved in 
these abnormalities [201]. Postweaning social isolation increases activity in novel 
environments, but data are controversial and the effect depends on the strain of rodents 
[136-138, 140, 192, 193, 202-206]. Most studies investigated motor activity during 
isolation, but social isolation by itself did not produce long-term changes in motor 
activity [106, 134]. Some reports suggest motor disturbances after NMDA antagonist 
treatment too, but the results are inconsistent, and the effect depends on the age of the 
animals [48, 161, 194]. Cessation of treatment in adult or juvenile rodents did not cause 
gross changes in motor activity, while early postnatal treatment was effective in this 
respect [48, 50, 130, 207]. Beninger’s laboratory investigated the effects of subchronic 
MK-801 treatment and postweaning social isolation on motor activity [86, 87, 208]. 
Postweaning social isolation enhanced locomotor activity, while MK-801 treatment 
alone, did not alter it, but blunted the amphetamine-induced hyperlocomotion. The 
combination of the two manipulations did not produce detectable additive or synergistic 
effects on behavior.  
In the present study, the complex analysis of motor activity during the NOR test 
revealed that the selective breeding decreased overall motor activity but increased the 
grooming behavior and no activity changes were observed in the capsaicin desensitized 
animals. Ketamine treatment + social isolation induced increased exploratory activity in 
both naive and selected groups. Interestingly, the complex treatment in selectively bred 
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animals resulted in an altered motor phenotype with decreased rearing and walking 
activity, accompanied by increased exploratory and grooming activities. The enhanced 
grooming behavior can indicate anxiety, and might present a useful strategy to 
investigate stress-related responses in animal models of neuropsychiatric disorders 
[209-211]. To clarify these results regarding the different aspects of motor behavior, 
further investigation of motor behavior is necessary in these animals. 
During telemetry monitoring we have found that the juvenile capsaicin desensitized 
animals showed increased activity during active phase under freely-moving 
circumstances. There are studies indicating that motor activity can be suppressed by the 
activation of TRPV1 receptors, for instance, low doses of capsaicin, its various analogs 
and anandamide inhibit ambulation, stereotypic behavior and activity in the open field 
test in a capsazepine-reversible manner [212-214]. Furthermore, dopamine transporter 
KO animals showed hyperlocomotion accompanied with decreased anandamide levels 
and upregulated TRPV1 receptors in the brain [85]. Findings about the effect of 
capsaicin desensitization on motor activity are inconsistent. Some authors found no 
major differences between capsaicin- or vehicle-treated animals in spontaneous and 
novelty-induced grooming, or in open-field exploration after either neonatal or adult 
capsaicin desensitization [175, 184]. Others observed that neonatally desensitized rats 
were hyperactive in new environments, and this hyperactivity was abolished by 
haloperidol [61]. A recent study found that TRPV1 KO animals showed slightly 
increased motor activity observed with the Minimitter device [184], while an earlier 
study showed that the deletion of the TRPV1 gene causes no changes in locomotion in 
the open field [81]. Most of the studies used short observation periods, sometimes as 
short as 15 min. Since we did not find significant differences in the activity in NOR test 
paradigm during a short period either, we suppose that brief investigation in these tests 
can not reveal the fine disturbance in motor activity. However, the telemetric method 
allows the long-term investigation of motor behavior of freely moving animals in their 
home cages. These data, together with earlier results, suggest that capsaicin 
desensitization can disturb the motor behavior for a long period, and as a putative 
explanation it is be proposed that a tonic activation of TRPV1 channels suppresses the 
general locomotor activity. Thus, the desensitized animals exhibited hyperactivity, as 
seen in certain types of schizophrenia.  
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6. Conclusions 
We developed a new substrain of rats by selective breeding after juvenile isolation and 
ketamine treatment showing several signs which resemble those found in schizophrenia. 
Our present results confirm that selective breeding is still one of the most fundamental 
and effective methods for the assessment of complex traits influenced by multiple 
genes. 
Reduced pain sensitivity, disturbed sensory gating, altered motor activity and decreased 
memory function were observed in the 15
th
 generation of the substrain. The summarized 
score based on categorization revealed that the selectively-bred and treated animals 
differed most markedly from the naive, non-treated rats. This suggests that genetically 
pre-disposed traits together with environmental risk factors resulted in the most 
prominent impairment relative to naive animals with no environmental perturbation. 
We firstly showed that juvenile capsaicin desensitization caused complete and long-
lasting abolishment of eye-wipe response and blepharospasm, as well as the urinary 
bladder capacity changes, suggesting the percent disturbance of TRPV1 receptors 
containing axons. Juvenile capsaicin desensitization did not change significantly heat 
and mechanical pain sensitivity; however, morphine produced a prolonged decrease in 
the nociceptive response to inflammation in capsaicin treated animals. The desensitized 
animals showed slight learning impairments and higher levels of activity indicating that 
capsaicin desensitization can cause some behavioral changes related to schizophrenia. 
 
In conclusion, further breeding is required to improve our animal model. Molecular 
biological studies are also required to reveal changes of various neurotransmitter 
systems and genetic abnormalities. We suppose that capsaicin desensitization together 
with other treatments (e.g. social isolation or ketamine treatment) could further improve 
the model. However, more work is needed to fully appreciate the role of TRPV1 
receptors in the CNS and hence, the potential central consequence of the 
pharmacological targeting of this channel with either agonists or antagonists with 
therapeutic activity. 
We suggest that the resulting rat line and complex treatment may serve as a potentially 
powerful model for the examination of the gene-environment interaction in the 
development of schizophrenia, and it can contribute to identify the symptoms and action 
mechanisms of the disease.  
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